Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OPXA's Cash to Debt is ranked higher than
94% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. OPXA: No Debt )
OPXA' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.71
OPXA's Equity to Asset is ranked higher than
76% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OPXA: 0.71 )
OPXA' s 10-Year Equity to Asset Range
Min: -1246   Max: 0.78
Current: 0.71

-1246
0.78
F-Score: 4
Z-Score: -6.66
M-Score: -1.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1066.86
OPXA's Operating margin (%) is ranked higher than
56% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. OPXA: -1066.86 )
OPXA' s 10-Year Operating margin (%) Range
Min: -2950   Max: -12.65
Current: -1066.86

-2950
-12.65
Net-margin (%) -1276.83
OPXA's Net-margin (%) is ranked higher than
55% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. OPXA: -1276.83 )
OPXA' s 10-Year Net-margin (%) Range
Min: -2200   Max: -6.13
Current: -1276.83

-2200
-6.13
ROE (%) -127.65
OPXA's ROE (%) is ranked higher than
54% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. OPXA: -127.65 )
OPXA' s 10-Year ROE (%) Range
Min: -797.04   Max: -19.44
Current: -127.65

-797.04
-19.44
ROA (%) -90.61
OPXA's ROA (%) is ranked higher than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. OPXA: -90.61 )
OPXA' s 10-Year ROA (%) Range
Min: -19900   Max: -15.39
Current: -90.61

-19900
-15.39
ROC (Joel Greenblatt) (%) -1170.53
OPXA's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. OPXA: -1170.53 )
OPXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14400   Max: -339.81
Current: -1170.53

-14400
-339.81
EBITDA Growth (%) -2.10
OPXA's EBITDA Growth (%) is ranked higher than
80% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. OPXA: -2.10 )
OPXA' s 10-Year EBITDA Growth (%) Range
Min: -67.4   Max: 43.4
Current: -2.1

-67.4
43.4
EPS Growth (%) -0.80
OPXA's EPS Growth (%) is ranked higher than
82% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. OPXA: -0.80 )
OPXA' s 10-Year EPS Growth (%) Range
Min: -64.4   Max: 49.6
Current: -0.8

-64.4
49.6
» OPXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
OPXA's P/B is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. OPXA: 2.20 )
OPXA' s 10-Year P/B Range
Min: 1.88   Max: 11
Current: 2.2

1.88
11
P/S 21.60
OPXA's P/S is ranked higher than
70% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. OPXA: 21.60 )
OPXA' s 10-Year P/S Range
Min: 16.9   Max: 78
Current: 21.6

16.9
78
EV-to-EBIT -0.85
OPXA's EV-to-EBIT is ranked higher than
77% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OPXA: -0.85 )
OPXA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.85

Current Ratio 4.79
OPXA's Current Ratio is ranked higher than
75% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. OPXA: 4.79 )
OPXA' s 10-Year Current Ratio Range
Min: 0.01   Max: 13.24
Current: 4.79

0.01
13.24
Quick Ratio 4.79
OPXA's Quick Ratio is ranked higher than
77% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. OPXA: 4.79 )
OPXA' s 10-Year Quick Ratio Range
Min: 0.01   Max: 13.24
Current: 4.79

0.01
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
OPXA's Price/Net Cash is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. OPXA: 3.00 )
OPXA' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 193.94
Current: 3

1.31
193.94
Price/Net Current Asset Value 3.00
OPXA's Price/Net Current Asset Value is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. OPXA: 3.00 )
OPXA' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 193.94
Current: 3

1.31
193.94
Price/Tangible Book 2.39
OPXA's Price/Tangible Book is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. OPXA: 2.39 )
OPXA' s 10-Year Price/Tangible Book Range
Min: 0.75   Max: 107.38
Current: 2.39

0.75
107.38
Price/Median PS Value 1.04
OPXA's Price/Median PS Value is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. OPXA: 1.04 )
OPXA' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 3.44
Current: 1.04

0.8
3.44
Forward Rate of Return (Yacktman) -72.78
OPXA's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. OPXA: -72.78 )
OPXA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -72.78

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:P6NN.Germany
Opexa Therapeutics, Inc., formerly known as Pharma was incorporated in Texas in March 1991. It is a biopharmaceutical company developing personalized cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS). These therapies are based on its proprietary T-cell technology. Information related to its product candidate is preliminary and investigative. Its product candidate, Tcelna, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS). It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. In September 2012, the company announced the initiation of a Phase IIb clinical trial of Tcelna in patients with SPMS. SPMS is characterized by a steady accrual of irreversible disability, despite, in some cases, reversible relapses, remissions or clinical plateaus. Older age at onset of MS diagnosis is the strongest predictor of conversion to SPMS. Males have a shorter time to conversion to SPMS compared with females. Its proprietary T-cell technology has enabled to develop intellectual property and a comprehensive sample database that may enable discovery of novel biomarkers and other relevant peptides to be used to treat MS patients. The Company has developed a proprietary adult stem cell technology to produce monocyte-derived stem cells (MDSC) from blood. These MDSC can be derived from a patient's monocytes, expanded ex vivo, and then administered to the same patient. The Company manufactures its TCV therapy in its own Good Manufacturing Practice `GMP' facility. The TCV technology used to produce Tovaxin is similar to that of traditional microbial vaccine technology, where the pathogen 'or the attenuated derivative' is used to derive the protective antigens necessary to induce protective immune responses. Its research and development activities and the future manufacturing and marketing of its potential products are, and would be, subject to regulation for safety and efficacy by a number of governmental authorities in the United States and other countries. Major pharmaceutical Companies currently offer a number of pharmaceutical products to treat MS, heart attack, stroke, Parkinson's disease, diabetes, liver diseases, arthritis and other diseases for which the company's technologies might be applicable. In the U.S., pharmaceuticals, biologicals and medical devices are subject to FDA regulation.
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 
Opexa Therapeutics Reports Second Quarter 2009 Financial Results and Corporate Update Aug 13 2009 

More From Our Partners
Stocks Hitting 52-Week Lows Sep 16 2014 - BENZINGA

More From Other Websites
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 16 2014
8:36 am Opexa Therapeutics announces termination of public offering of common stock Sep 16 2014
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock Sep 16 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 15 2014
Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Sep 15 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 08 2014
Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program Sep 08 2014
Opexa Therapeutics to Present at September Conferences Sep 02 2014
OPEXA THERAPEUTICS, INC. Financials Aug 22 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 14 2014
OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
Opexa Therapeutics Reports Second Quarter 2014 Financial Results and Provides Corporate Update Aug 14 2014
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter... Aug 11 2014
RedChip Issues Research Profile on Opexa Therapeutics Jul 17 2014
RedChip's July 16-17 Global Online CEO Conference Presentation Schedule Now Available Jul 08 2014
Opexa Therapeutics Joins Russell Microcap Index Jun 30 2014
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg Jun 26 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 25 2014
Opexa Is Personalizing The Treatment Of Autoimmune Disease Jun 03 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK